<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01971502</url>
  </required_header>
  <id_info>
    <org_study_id>1333.1</org_study_id>
    <secondary_id>2013-001475-20</secondary_id>
    <nct_id>NCT01971502</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses and Effect of Food on the Bioavailability of BI 1060469</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of BI 1060469 in Healthy Male Volunteers (Single-blind, Placebo-controlled, Randomised, Partly Fixed-sequence, Parallel Group Design) and Effect of Food on the Bioavailability of BI 1060469 (Open-label, Randomised, Two-way Cross-over)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the single rising dose part (SRD) is to investigate safety, tolerability,
      pharmacokinetics, and pharmacodynamics of single rising doses of BI 1060469 in healthy male
      subjects. The objective of the food effect part (FE) is to investigate the relative
      bioavailability of BI 1060469 tablets in healthy male subjects in fed or fasted state.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with drug- related adverse events.</measure>
    <time_frame>up to 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of BI 1060469 in plasma)</measure>
    <time_frame>up to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of BI 1060469 in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of BI 1060469 in plasma over the time interval from 0 up to the last quantifiable data point)</measure>
    <time_frame>up to 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 1060469 single rising dose part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single rising doses given as tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1060469 food effect part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given as tablet fasted and fed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 1060469</intervention_name>
    <description>single rising doses</description>
    <arm_group_label>BI 1060469 single rising dose part</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1060469</intervention_name>
    <description>food effect</description>
    <arm_group_label>BI 1060469 food effect part</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1060469</intervention_name>
    <description>single rising doses</description>
    <arm_group_label>BI 1060469 single rising dose part</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males based upon a complete medical history, including a physical examination,
             vital signs (blood pressure, pulse rate), 12-lead electrocardiogram, and clinical
             laboratory tests

          2. Age within the range of 18 to 50 years

          3. Body mass index within the range of 18.5 and 29.9 kg/m2

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with good clinical practice (GCP) and local legislation.

        Exclusion criteria:

          1. Any finding in the medical examination (including blood pressure (BP), pulse rate (PR)
             or electrocardiogram (ECG)) deviating from normal and judged clinically relevant by
             the investigator. Pulse rate outside the range of 50-90 bpm or blood pressure outside
             the ranges of 90-140 for systolic and 50-90 mmHg for diastolic blood pressure if
             confirmed by repeat measurement.

          2. Any laboratory value outside the reference range that the investigator considers to be
             of clinical relevance

          3. In the SRD: serum creatinine laboratory value outside the normal range

          4. Glomerular filtration rate (GFR) according to CKD-EPI (Chronic Kidney Disease -
             Epidemiology Collaboration)-Formula &lt; 60 ml/ min

          5. Current or history of relevant kidney, urinary tract diseases or abnormalities (i.e.
             nephrolithiasis, hydronephrosis, acute or chronic nephritis, renal injury, renal
             failure, infections)

          6. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          7. Surgery of the gastrointestinal tract that could interfere with kinetics of the study
             drug
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1333.1.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2013</study_first_posted>
  <last_update_submitted>October 24, 2014</last_update_submitted>
  <last_update_submitted_qc>October 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

